Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

115.96 +1.93 (+1.69%)
Delayed Quote Updated: 2:07 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Corcept Announces Planned Leadership Transition
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
CORCEPT DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class Action – CORT
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
CORCEPT DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Corcept Therapeutics Incorporated Investors to Contact the Firm Regarding Their Rights Before April 21st
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Deadline Soon: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
From SkyMedia, LLC
Via GlobeNewswire
News headline image
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
CORT SHAREHOLDER ACTION ALERT: Kaplan Fox Alerts Investors of a Class Action Lawsuit Against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Lead Plaintiff Deadline on April 21, 2026
NEW YORK, NY - April 13, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ:... 
Via TheNewswire.com
Topics Lawsuit
News headline image
CORT SHAREHOLDER ACTION ALERT: Kaplan Fox Alerts Investors of a Class Action Lawsuit Against Corcept Therapeutics, Inc. (NASDAQ: CORT) and Lead Plaintiff Deadline on April 21, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
DEADLINE ALERT: Kaplan Fox Alerts Investors to a Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Deadline is April 21, 2026
NEW YORK, NY - April 11, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ:... 
Via TheNewswire.com
Topics Lawsuit
News headline image
DEADLINE ALERT: Kaplan Fox Alerts Investors to a Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Deadline is April 21, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Securities Class Action Deadline Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Contact Kaplan Fox Before April 21, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Securities Class Action Deadline Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Contact Kaplan Fox Before April 21, 2026
NEW YORK, NY - April 10, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ:... 
Via TheNewswire.com
Topics Lawsuit
News headline image
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
From SkyMedia, LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.